Spesolimab (Spevigo)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses spevigo (spesolimab for injection), 900 mg (60 mg/mL), concentrate for solution for IV infusion. Indication: For the treatment of generalized pustular psoriasis in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.